Genomic landscape and homologous recombination deficiency in malignant germ cell tumors reveals sex‐specific therapeutic opportunities
The Journal of Pathology · 2026-06 · 269 (2) · 210-221
DOI: 10.1002/path.70047 ↗At a glance
Journal article in The Journal of Pathology, published online on 2026-03-14. Written by Boheng Xu and 4 co-authors. Institution: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Major MEDLINE topics: Neoplasms, Germ Cell and Embryonal, Homologous Recombination, Testicular Neoplasms. 38 references.
Abstract (original language)
Malignant germ cell tumors (GCTs) are relatively rare tumors with limited therapeutic options. This study examined the homologous recombination deficiency (HRD) status and genomic characteristics in 14 patients with GCT who underwent next‐generation sequencing. HRD was evaluated using the genomic instability score (GIS), which incorporates three components: loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large‐scale transition (LST). Our findings showed that 57.1% (8/14) of participants were HRD positive. Female patients presented a significantly higher prevalence of HRD positivity (87.5%, 7/8) compared with male patients (16.7%, 1/6). HRD positivity in female cases had a mean GIS of 56 (range 48–76), including one patient harboring a germline BRCA2 p.S2670L (c.8009C>T) likely pathogenic mutation. LST demonstrated the strongest correlation with the integrated GIS ( R 2 = 0.945), followed by LOH ( R 2 = 0.872). Distinct mutation patterns were observed based on gender. GCTs in male cases predominantly exhibited mutations in TP53 (50% in yolk sac tumors; 50% in teratomas). GCTs in male cases also demonstrated TP53 mutations in one mediastinal yolk sac tumor and one mediastinal teratoma. Male cases showed recurrent alterations in KRAS , PRKDC , and CDKN1B , alongside frequent chromosome 12p amplifications in two cases. One particularly complex mediastinal teratoma in a male patient, featuring rhabdomyosarcomatous transformation, displayed bidirectional intergenic ( TWSG1, MANEA‐DT )‐ROS1fusions, a HRAS ‐intergenic ( RNH1 ) fusion, and MET focal amplification. These findings suggest a promising therapeutic opportunity with poly (ADP‐ribose) polymerase (PARP) inhibitors for female patients with HRD‐positive GCTs. Additionally, the complex composition of gene variants found in male patients with GCTs, including ROS1 fusions and MET focal amplification, points toward potential targeted therapeutic strategies. This study underscores the presence of sex‐specific therapeutic vulnerabilities in GCTs, which warrant further exploration in larger cohorts. © 2026 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
- Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, PR China.
- Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
- Department of Head and Neck, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, PR China.
ORCID profiles: Caiyun He
Cite
APA
Xu, B., Chen, J., Peng, H., Su, X., & He, C. (2026). Genomic landscape and homologous recombination deficiency in malignant germ cell tumors reveals sex‐specific therapeutic opportunities. The Journal of Pathology, 269(2), 210-221. https://doi.org/10.1002/path.70047
Vancouver
Xu B, Chen J, Peng H, Su X, He C. Genomic landscape and homologous recombination deficiency in malignant germ cell tumors reveals sex‐specific therapeutic opportunities. The Journal of Pathology. 2026;269(2):210-221. doi:10.1002/path.70047
BibTeX
@article{Xu2026,
author = {Xu, Boheng and Chen, Jiahong and Peng, Huiting and Su, Xuan and He, Caiyun},
title = {Genomic landscape and homologous recombination deficiency in malignant germ cell tumors reveals sex‐specific therapeutic opportunities},
journal = {The Journal of Pathology},
year = {2026},
volume = {269},
number = {2},
pages = {210--221},
doi = {10.1002/path.70047}
}
EUVIMED